New and Interesting Benefits with New Molecules in Obesity and Type 2 Diabetes

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective therapies for managing type 2 diabetes mellitus (T2DM) and obesity. These agents mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety. Mechanistically, GLP-1 RAs target the GLP-1 receptor, predominantly found in pancreatic β-cells, the gastrointestinal tract, and the central nervous system, leading to improved glycemic control with a reduced risk of hypoglycemia. Their weight-loss benefits stem from delayed gastric emptying and central appetite suppression, while cardiovascular benefits, such as reduced major adverse cardiovascular events, make them integral to T2DM treatment. GLP-1 RAs differ in pharmacokinetics, with short-acting agents, like exenatide, targeting postprandial glucose, and long-acting options, like liraglutide and semaglutide, offering sustained fasting and postprandial glucose control. Semaglutide, available as both injectable and oral formulations, has demonstrated superior efficacy in weight reduction and glycemic outcomes compared to its counterparts. Additionally, emerging dual and triple agonists targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, such as tirzepatide, represent a novel therapeutic frontier, amplifying metabolic benefits with substantial weight loss and improved glycemic control. While GLP-1 RAs are generally well-tolerated, gastrointestinal side effects, such as nausea and vomiting, remain the most common adverse events. Long-term safety, particularly concerning pancreatitis and gallbladder disease, requires further study. Nonetheless, their efficacy and safety profiles solidify their role as cornerstone therapies for metabolic diseases. Ongoing advancements in multi-agonist therapies promise enhanced therapeutic outcomes and broader clinical utility in the management of T2DM and obesity.